Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 7809 - 7816 of 12086 results

Senators Ask DOJ to Investigate EpiPen-Maker Mylan
September 28, 2016| News

Employer’s No Dreadlock Policy Did Not Violate Title VII, Says Eleventh Circuit
September 27, 2016| Blog| Viewpoint

Second Circuit: “C” is for Comity; Price Fixing Judgment Against Chinese Vitamin C Sellers Reversed
September 27, 2016| Alert| Viewpoint

Court in LendingClub Class Action Requires Due Diligence by Lead Plaintiff Before Approving Lead Counsel
September 27, 2016| Blog| Viewpoint

FDA Holding its First Public Meeting on Drug Product Identification Requirements in October
September 27, 2016| Blog| Viewpoint

DOJ Loss In AmEx Case Could Imperil Hospital Steering Suit
September 27, 2016| News

Hospital Merger Stalls After FTC Court Win
September 27, 2016| News

H-1B Class Action Could Bring Needed Transparency
September 27, 2016| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
